We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...

Eli Lilly and Company LLY announced that the FDA has granted a Breakthrough Therapy designation to its novel folate receptor ...

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...

Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE ® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for mirvetuximab soravtansine (an antibody-drug conjugate therapy), emphasizing ...

Figure 1: Panel of various pediatric tumors comparing H&E staining, FRα, and FRβ protein expression within the tumor. None of these tumors demonstrate FRα expression; however all of the tumors ...

AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...